Enhancing Recovery after Radical Prostatectomy
At Levee Medical, we are committed to designing solutions that aim to reduce complications associated with surgical treatment.
One in 8 men will develop prostate cancer*
Patients often choose surgery to treat prostate cancer
In most cases, surgery enables complete and immediate removal of cancer.
Urinary incontinence after prostatectomy remains a debilitating problem
It is the most feared complication following surgery for prostate cancer.
Return to daily life quicker and with confidence
Our goal is to minimize incontinence so that patients can turn the page after prostate cancer surgery.
The first and only bioresorbable device to address urinary incontinence in radical prostatectomy patients
Focused on Recovery
Founder & CTO
Executive Vice President
Clinical and Regulatory Affairs
Jeffrey Dann, M.D.
Michael Ferrandino, M.D.
Jeffrey Gahan, M.D.
Duke Herrell, M.D.
Lee Ponsky, M.D.
Levee Medical Secures $4.3M Strategic Investment to Accelerate Clinical Development of the Voro™ Urologic Scaffold, Designed to Improve Robotic Prostatectomy Outcomes
Milestone Achieved as Company Announces Successful Enrollment of First Patients in its First-in-Human (FIH) Study
DURHAM, NC – Sept. 6, 2023 – Levee Medical, a clinical-stage medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has raised a total of $4.3 million in oversubscribed funds. Additionally, Levee Medical successfully treated the first study participants in its first-in-human (FIH) study, demonstrating initial safety data for the Voro™ Urologic Scaffold.
Company to Accelerate Development of Novel Urologic Device Designed to Improve Recovery Outcomes Post-Prostatectomy
Durham, NC – August 23, 2022 – Levee Medical, a medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has closed an initial oversubscribed series A financing round, raising a total of $6.6 million. The funds will be used to advance product development, scale infrastructure, and expand the team to support the development of the company’s Voro™ Urologic Scaffold, a bioresorbable post-prostatectomy implant.